MedTrace Logo

A Performance Evaluation of the LumiraDx Point of Care CRP Assay

NCT05180110 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2023-12-19

No results posted yet for this study

Summary

In patients with symptoms of infection, tissue injury and inflammatory disorders the study will evaluate agreement between the CRP measurements from the LumiraDx POC CRP assay and the Siemens Dimension Xpand Plus CRP assay, as an aid in evaluation and detection of infection, tissue injury and inflammatory disorders.

Conditions

Interventions

DIAGNOSTIC_TEST

Venepuncture

Venous blood draw

DIAGNOSTIC_TEST

Fingerstick

Capillary blood draw

Sponsors & Collaborators

  • LumiraDx UK Limited

    lead INDUSTRY

Principal Investigators

  • Alasdair Gray, MD · NHS Lothian

  • James Harnett · University College London Hospital NHS Foundation Trust

  • Phil Moss · St Georges University Hospitals NHS Foundation Trust

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-25
Primary Completion
2022-01-11
Completion
2023-05-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05180110 on ClinicalTrials.gov